Blood protein tracked advanced CTE in ex-football players, two small studies find
The marker could one day let doctors spot the brain disease before death, but so far it has only shown promise for late-stage cases in a few dozen donors.

A protein found in blood tracked with advanced chronic traumatic encephalopathy in former football players, according to new research. It is a first step toward diagnosing CTE in living people, not only at autopsy.
The findings come from two studies in the medical journal JAMA. A team from Boston University and Banner Health published its study Thursday. The previous Friday, a group from the Washington University School of Medicine in St. Louis published a separate study that identified the same blood biomarker, working from 11 cases.
CTE is a degenerative brain disease linked to repeated hits to the head in football and other contact sports, and it can currently be confirmed only after death. The U.S. Food and Drug Administration has not approved any test or treatment specific to the disease. Researchers have wanted a reliable test in the living for years, because without one they cannot tell who has the disease, track how it develops or enroll patients in drug trials.
The design is what makes the Boston result worth taking seriously. Former football players gave blood samples while they were alive. After they died, autopsies of their brains confirmed CTE. The researchers then went back to the stored blood and measured levels of a specific protein, so they could compare the blood readings against a definitive diagnosis rather than against symptoms or guesses.
The study covered 21 deceased players. Twelve had played professionally, seven had played through college and two had stopped after high school. Autopsies found advanced-stage CTE in most of the former pros, in four of the college players and in one of the high school players. Those players had higher concentrations of the protein in their blood. The five players who had both CTE and Alzheimer's disease showed the highest levels of all.
Michael Alosco, co-director of clinical research at Boston University's CTE Center and a co-senior author of the study, described the test as a "game changer" for diagnosing the disease in living people. He was also careful about how far the evidence goes.
"We are still in the discovery phase and it's a small sample size," Alosco said in a statement.
He added that if future studies confirm the results, the test could detect CTE with high accuracy and open the door to clinical trials and treatment.
That caution is warranted. Twenty-one people is a very small group for a diagnostic study, and the work looked back at stored samples rather than testing people prospectively. The Washington University result helps, because a second, independent team landed on the same biomarker. But 11 more cases does not change the basic picture: this is an early signal, not a validated test.
The most important limit is timing. The Boston test showed promise only for advanced CTE. It did not show it could pick up the disease in its early stages, which are often free of symptoms. By the advanced stages, patients tend to have symptoms such as memory loss, confusion, depression, irritability and severe mood swings.
So the test, as it stands, would mostly confirm disease in people who are already showing signs of it. That still matters. Families of retired players with those symptoms often have no way to learn the cause while their relative is alive, and researchers cannot test treatments on patients they cannot identify. But a test that catches CTE only late does little to help anyone change course before the damage is done.
The Alzheimer's finding raises a separate question. If the protein runs highest in people who have both diseases, future studies will need to show how well the marker separates CTE from Alzheimer's on its own. That distinction matters for any older patient with memory problems, and the published numbers don't settle it.
This is not the first attempt to diagnose CTE in life. In 2017, researchers said they had used a brain scan to identify the disease in a former NFL player while he was still alive, and work on scans continues. A blood test, if it holds up, would be cheaper and easier to repeat than imaging. Doctors could check patients over time, which scans make harder. That practical advantage is why this line of research draws so much attention.
A working test would also force decisions that players and families have not had to make before, from youth leagues to the NFL. One of the most direct: whether active players would want to know.
ESPN asked more than 30 current and former NFL players last summer whether they would take a CTE test if one existed. Marcus Mariota, identified as the Washington Commanders quarterback, said yes, arguing that results would give insight "to the rest of the NFL, to college kids, to high school kids" about what the game involves.
Minnesota Vikings safety Joshua Metellus said he probably would not want testing while still playing, "because I think it'll change the way I play." He acknowledged that many players are curious and would want to know.
Those two answers capture the tension well. For now, though, the dilemma is mostly hypothetical for active players. A test that works only for advanced disease is far more relevant to retirees than to someone in the middle of a career. The harder questions arrive if researchers can push detection into the early, symptom-free stages. That is when a result could plausibly shape decisions about whether to keep playing.
Alosco's own timeline is measured. He told ESPN he hopes to understand the finding and "move it forward in the next five years or so." Given the sample sizes so far, the next milestone to watch for is a larger study that tests the marker in living people and then follows them, not just a re-analysis of donated samples.




